Insights, challenges, and future directions in irinogenetics

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 265-270

  Kim, Tae Won ^a   Innocenti, Federico ^b  

^a University of Ulsan   (South Korea)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Irinogenetics; Irinotecan; Pharmacogenetics; UGT1A1

Indexed keywords

7 ETHYL 10 [4 N(1 PIPERIDINO) 1 AMINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 [4 N(5 AMINOPENTANOICACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ABC TRANSPORTER; CAPECITABINE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; CARBOXYLESTERASE 3; CISPLATIN; CYTOCHROME P450; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE;

AREA UNDER THE CURVE; BLOOD TOXICITY; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG USE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; GLUCURONIDATION; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; METASTASIS; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ASIAN; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; NEOPLASM; PHENOTYPE; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; NEOPLASMS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 34347371390     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318068623b     Document Type: Review

References (47)

1. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997;33:245-259.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
3. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91.
4. Innocenti F, Ratain MJ. 'Irinogenetics' and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004;75:495-500.
5. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998;101:847-854.
6. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999;65:576-582.
7. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003;9:3246-3253.
8. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723-3725.
9. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-47.
10. Satoh T, Hosokawa M. Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicol Lett. 1995;82-83:439-445.
11. Morton CL, Iacono L, Hyatt JL, et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol. 2005;56:629-636.
12. Wu MH, Chen P, Wu X, et al. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics. 2004;14:595-605.
13. Kim SR, Nakamura T, Saito Y, et al. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet. 2003;18:327-332.
14. Marsh S, Xiao M, Yu J, et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004;84:661-668.
15. Charasson V, Bellott R, Meynard D, et al. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther. 2004;76:528-535.
16. Monaghan G, Ryan M, Seddon R, et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 1996;347:578-581.
17. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
18. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis. 2003;31:98-101.
19. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95:8170-8174.
20. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecanadministered Japanese patients with cancer. Clin Pharmacol Ther. 2004;75:501-515.
21. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004;44:854-860.
22. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-1388.
23. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004;10:5151-5159.
24. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-3068.
25. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004;91:678-682.
26. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer. 2006;106:1007-1016.
27. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.
28. Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005;11:1226-1236.
29. Font A, Sanchez JM, Taron M, et al. Weekly regimen of irinotecan/ docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs. 2003;21:435-443.
30. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006;24:2237-2244.
31. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 2003;31:108-113.
32. Yamamoto K, Sato H, Fujiyama Y, et al. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta. 1998;1406:267-273.
33. Koiwai O, Nishizawa M, Hasada K, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP- glucuronosyltransferase. Hum Mol Genet. 1995;4:1183-1186.
34. Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol. 2006;24:2221-2224.
35. Villeneuve L, Girard H, Fortier LC, et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003;307:117-128.
36. Yamanaka H, Nakajima M, Katoh M, et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 2004;14:329-332.
37. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501-515.
38. Innocenti F, Liu W, Chen P, et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005;15:295-301.
39. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003;13:741-757.
40. Michael M, Thompson M, Hicks RJ, et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol. 2006;24:4228-4235.
41. Zhou Q, Sparreboom A, Tan EH, et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol. 2005;59:415-424.
42. Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes. Proc ASCO. 2005;23:2006a.
43. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81:42-49.
44. Nozawa T, Minami H, Sugiura S, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33:434-439.
45. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006;24:4534-4538.
46. Innocenti F, Undevia SD, Chen PX, et al. Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: evidence for a functional variant of ABCC2. Proc ASCO. 2004;22:2010a.
47. Innocenti F, Janisch L, Das S, et al. A genotype-directed phase I study of irinotecan in advanced cancer patients. Proc ASCO. (in press).